PLASMINOGEN ACTIVATORS AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN URINARY-TRACT CANCER

被引：14

作者：

BASHAR, H ^{[1
]}

URANO, T ^{[1
]}

FUKUTA, K ^{[1
]}

PIETRASZEK, MH ^{[1
]}

HATA, M ^{[1
]}

SUZUKI, K ^{[1
]}

KAWABE, K ^{[1
]}

TAKADA, Y ^{[1
]}

TAKADA, A ^{[1
]}

机构：

[1] HAMAMATSU UNIV SCH MED, DEPT UROL, HAMAMATSU, SHIZUOKA 43131, JAPAN

来源：

UROLOGIA INTERNATIONALIS | 1994年 / 52卷 / 01期

关键词：

TISSUE-TYPE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENAL CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA;

D O I：

10.1159/000282560

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The plasminogen activation system is considered to play an important role in cancer growth and metastasis. Both plasminogen activators (PAs) and their fast-acting inhibitors are produced in tumor cells and their surrounding tissues. In order to clarify the influence of the existence of malignant tumor in urinary tract on the systemic fibrinolytic activity, we designed a study in which we compared the plasma levels of PAs and their inhibitors between before and after radical resection of tumors. Fourteen patients with renal cell carcinoma and 14 patients with transitional cell carcinoma participated in the study. In both groups,: plasma levels of tissue-type plasminogen activator and urokinase-type plasminogen activator before the operation were higher than those 15 days after operation. The plasma level of plasminogen activator inhibitor 1 (PAI-1), however, did not change after the operation in the renal cell carcinoma group, and it decreased slightly in the transitional cell carcinoma group although it was not significant. When these values of the groups with or without metastasis were compared to other organs or lymph nodes, the PAI-1 level before operation was significantly higher in the group with metastasis than that without metastasis. In the three groups divided by the degree of atypia, PAI-1 level in the most atypical group was the highest. These results suggest that the fibrinolytic system in the plasma of cancer patients may play an important role in tumor growth and metastasis.

引用

页码：4 / 8

页数：5

共 27 条

[1]

Castellino F.J., Biochemistry of human plasminogen, Semin Thromb Hemost, 10, pp. 18-23, (1983)

[2]

Camiolo S.M., Markus G., Evers J.L., Hobika G.H., Dcpasqualc J.L., Bcckley S., Grimaldi J.P., Plasminogen activator content of neoplastic and benign human prostate tissues, Int J Cancer, 27, pp. 191-198, (1981)

[3]

Nelson N.F., Cieplak W., Dacus S.C., Prager M.D., Characterization of plasminogen activator from two human renal cell carcinoma cell lines, J Cell Physiol, 126, pp. 435-443, (1986)

[4]

Takada A., Takada Y., Plasminogen activators: Possible roles in cell proliferation, Dermatolo- Gica, 179, pp. 77-83, (1989)

[5]

Kirchhcimer J.C., Pfliiger H., Hiencrt G., Binder B.R., Increased urokinase activity to antigen ratio in human renal cell carcinoma, Int J Cancer, 35, pp. 737-741, (1985)

[6]

Astedt B., Lccander I., Ny T., The placental type plasminogen activator inhibitor. PAI-2, Fibrinolysis, 1, pp. 203-208, (1987)

[7]

Loskutoff D.J., Sawdcy M., Mimuro J., Type 1 plasminogen activator inhibitor

[8]

in BS Coller (ed), Progress in Haemostasis and Thrombosis, 9, pp. 87-115, (1988)

[9]

Urano T., Sumiyoshi K., Pietraszek M.H., Takada Y., Takada A., PAI-1 Plays an Important Role in the Expression of Tpa Activity in the Euglobulin Clot Lysis by Controlling the Concentration of Free Tpa Thromb Hacmost, 66, pp. 474-478, (1991)

[10]

Lecave R., Rondeau E., Ochi S., Dclarue F., Schleuning W.D., Sraer J.D., Characterization of a plasminogen activator and its inhibitor in human mesangial cells, Kidney Int, 35, pp. 806-811, (1989)

← 1 2 3 →